drugset / Trial / NCT06425003

Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

NCT06425003

Phase 1 Completed 7 enrolled Calico Life Sciences LLC AbbVie · collab
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-CLS-7262 in healthy, male volunteers following administration of a single oral dose.

Timeline

Start
2024-05-21
Primary completion
2024-07-12
Completion
2024-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-CLS-7262 Unknown Oral

Indications

No indication recorded.